BioSpace News Archive

Royal Philips, a global leader in health technology, announced the results of its Future Health Index 2023 report: Taking healthcare everywhere.

Ashvattha Therapeutics (“Ashvattha”) today announced preclinical data showing its potent macrophage switching nanomedicine, D-4559, reduces tumor growth in a mouse model of hepatocellular carcinoma (HCC).

Immuneering Corporation announced positive initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which are being shared today in a poster presentation titled “Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors” (abstract #4265) at the American Association for Cancer Research (AACR) annual meeting.

Erasca, Inc. (Nasdaq: ERAS) today presented promising initial Phase 1b dose escalation data from FLAGSHP-1 for ERAS-601 in combination with cetuximab (ERBITUX®) in patients with advanced solid tumors as part of a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announced data from a poster showing two patient case studies from a clinical trial of its lead candidate cell therapy APN401 during the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring preclinical data on naxitamab, a recombinant, humanized anti-GD2 monoclonal antibody will be presented at the AACR Annual Meeting 2023.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 first quarter on Tuesday, May 9, 2023 before the open of the U.S. financial markets.

Serenus.AI launches the first patented autonomous clinically objective, Generative AI, case-by-case review system to improve the utilization and prior-authorization processes before medical procedures.

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics, today announced the details of the Company’s presentation at the 2023 AACR Annual Meeting on its lead asset, TAC01-HER2, for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2023 Bloom Burton & Co. Healthcare Investor Conference.